Budget Impact of Adding Vedolizumab to a Health Plan Formulary as Another First-Line Biologic Option for Ulcerative Colitis and Crohn's Disease.

Wilson, Michele; Lucas, Aaron; Cameron, Ann; Luo, Michelle

Wilson, Michele; Lucas, Aaron; Cameron, Ann; Luo, Michelle.

Afiliación

Wilson M; Director of Health Economics, RTI Health Solutions, Research Triangle Park, NC.
Lucas A; Senior Health Economist, RTI Health Solutions.
Cameron A; Associate Director of Global Health Economics and Outcomes Research, Xcenda LLC, Palm Beach, FL.
Luo M; Head of GI Global Outcomes Research, Takeda Pharmaceuticals, Cambridge, MA.

Am Health Drug Benefits ; 11(5): 253-262, 2018 Jul.

Article en En | MEDLINE | ID: mdl-30464793

Palabras clave

Crohn's disease; adalimumab; anti-TNF biologic drug; budget impact model; certolizumab; golimumab; health plan formulary; infliximab; ulcerative colitis; vedolizumab

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Health_economic_evaluation / Prognostic_studies Idioma: En Revista: Am Health Drug Benefits Año: 2018 Tipo del documento: Article País de afiliación: Nueva Caledonia

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google